BioSpace News Archive

The global Gene Synthesis Market size is expected to hit around US$ 10.58 billion by 2030 and is anticipated to grow at a CAGR of 19.1% during forecast period 2021 to 2030.

Freeline Therapeutics Holdings plc announced that on April 29, 2022, the Company granted five newly hired employees non-statutory options to purchase an aggregate of 57,850 of the Company’s ordinary shares.

Ultragenyx Pharmaceutical Inc. announced that Camille Bedrosian, M.D., the company’s Chief Medical Officer, and Mardi Dier, the company’s Chief Financial Officer, will present at the BofA Securities 2022 Healthcare Conference on Tuesday, May 10, 2022 at 5:40 PM ET.

HilleVax, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, announced the closing of its initial public offering of 13,529,750 shares of common stock, which includes the exercise in full by the underwriters of their option to purchase 1,764,750 additional shares, at an initial public offering price of $17.00 per share.

Brickell Biotech, Inc. announced that its 2022 annual meeting of stockholders has been adjourned to Tuesday, May 17, 2022 at 10 a.m. Mountain Time with respect to all proposals described in Brickell’s definitive proxy statement filed with the U.S. Securities and Exchange Commission on March 22, 2022.

Inspire Medical Systems, Inc. reported financial results for the quarter ended March 31, 2022.

Rigel Pharmaceuticals, Inc. reported financial results for the first quarter ended March 31, 2022, including sales of TAVALISSE® tablets for the treatment of adults with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.

Cumberland Pharmaceuticals Inc., a specialty pharmaceuticals company, announced that it will release the first quarter 2022 financial results and provide a company update after the market closes on Tuesday, May 10, 2022.

Heron Therapeutics, Inc. announced that the company will host a conference call and live webcast on Monday, May 9, 2022 at 4:30 p.m. ET to report first quarter 2022 financial results and discuss recent business highlights.

Spruce Biosciences, Inc. announced that company management will participate in two upcoming investor conferences taking place in May.